|
Combined Hormone Replacement in Menstrually-Related Mood Disorders Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Combined Hormone Replacement in Menstrually-Related Mood Disorders conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combined Hormone Replacement in Menstrually-Related Mood Disorders Clinical research trials and Combined Hormone Replacement in Menstrually-Related Mood Disorders health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Combined Hormone Replacement in Menstrually-Related Mood Disorders. Combined Hormone Replacement in Menstrually-Related Mood Disorders Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Combined Hormone Replacement in Menstrually-Related Mood Disorders clinical trial. Test subjects typically receive the most expert healthcare available for their Combined Hormone Replacement in Menstrually-Related Mood Disorders condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combined Hormone Replacement in Menstrually-Related Mood Disorders  Combined Hormone Replacement in Menstrually-Related Mood Disorders
Combined Hormone Replacement in Menstrually-Related Mood Disorders
For Condition: Premenstrual Syndrome
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to investigate the role of the hormones estrogen and progesterone in women with premenstrual syndrome (PMS). Studies indicate that women with PMS experience improvement in symptoms following treatment with leuprolide acetate, when estrogen and progesterone levels are low. Women with PMS, but not women without the disorder, experience a return of symptoms within approximately a week after re-exposure to either estrogen or progesterone. The cause of this hormone-induced depression remains unclear. It is not known whether this depressed mood is due simply to the change in the levels of estrogen and progesterone and whether it would remit following continued exposure to stable levels of estrogen and progesterone. This study will determine whether the maintenance of stable hormone levels will prevent mood disturbances in women with PMS. Participants in this study will receive leuprolide acetate injections once a month for up to 6 months. After 2 months, women whose symptoms have improved will receive a skin patch containing either estrogen or placebo (an inactive substance) and will be asked to take daily suppositories containing either progesterone or placebo. Women whose symptoms of PMS do not respond to leuprolide treatment after 2 months will end the study and be offered other treatment. Participants will be seen by a nurse in the clinic every two weeks and will fill out ratings and have blood drawn to measure hormone levels.
Details: Results from previous protocols (#90-M-0088 and 92-M-0174) have demonstrated that women with menstrually-related mood disorder (MRMD), but not women lacking this disorder, experience mood deterioration within approximately a week after exposure to either estradiol or progesterone in the context of gonadal suppression (induced by use of the depot gonadotropin releasing hormone agonist, leuprolide acetate). It is unknown whether this hormone-induced depression occurs consequent to changes in gonadal steroid levels or to simple exposure to levels above a critical threshold. Additionally, since the symptoms of depression stimulated by hormone addback appeared to remit by the fourth week of hormone administration, it is unclear whether continued administration of hormone would result in continued or repeated experience of depression or whether no further symptoms would appear subsequent to the initial precipitated episode. To address these points of uncertainty, we first will establish the efficacy of gonadal suppression in our MRMD subjects by administering depot leuprolide acetate for three months and then will administer both estradiol and progesterone in a continuous fashion for three months to determine whether maintenance of stable gonadal steroid levels will prevent the characteristic cyclic mood disorder.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: INCLUSION CRITERIA: History within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress and interference with life activities. Symptoms with a sudden offset and absence of significant symptomatology during the follicular phase. Age 18-50. Regular menstrual cycles (21-35 days in length), not pregnant, and in good medical health. Medication free. No subjects taking birth control pills or psychotropic agents (e.g. Antidepressants, anxiolytics, or lithium carbonate). EXCLUSION CRITERIA: Any patient with a current axis I psychiatric diagnosis will be excluded.
Total Enrollment: 35
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Linda Clair 3014969576
Additional Information:
Study ID Numbers: 000103; 00-M-0103
Study Start Date: March 28, 2000
Record last reviewed: March 15, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005011
Other Premenstrual Syndrome Studies:
1. Combined Hormone Replacement in Menstrually-Related Mood Disorders
2. Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
3. Altered Calcium and Vitamin D in PMDD or Severe PMS
Related Studies:
Other Premenstrual Syndrome Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Combined Hormone Replacement in Menstrually-Related Mood Disorders
|
|
|
|
|
|
|
|
